
## **Daniel Eiger**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7123441/publications.pdf Version: 2024-02-01



DANIEL FICER

#	Article	IF	CITATIONS
1	The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers, 2021, 13, 1015.	3.7	83
2	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Annals of Oncology, 2019, 30, x27-x42.	1.2	63
3	Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Journal of Clinical Oncology, 2022, 40, 2946-2956.	1.6	46
4	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 148, 76-91.	2.8	33
5	Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center. BMC Palliative Care, 2018, 17, 13.	1.8	27
6	Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. British Journal of Cancer, 2020, 122, 1453-1460.	6.4	22
7	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. Journal of the National Cancer Institute, 2021, 113, 462-470.	6.3	20
8	Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. Breast Cancer Research and Treatment, 2020, 181, 199-209.	2.5	19
9	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. Future Oncology, 2019, 15, 1823-1843.	2.4	14
10	Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: a critical review. Anais Brasileiros De Dermatologia, 2018, 93, 553-558.	1.1	8
11	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers, 2022, 14, 2596.	3.7	8
12	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta OncolÃ <sup>3</sup> gica, 2020, 59, 723-725.	1.8	7
13	Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open, 2020, 5, e000659.	4.5	6
14	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. Breast, 2021, 57, 86-94.	2.2	6
15	Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial Journal of Clinical Oncology, 2021, 39, 510-510.	1.6	3
16	Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. ESMO Open, 2020, 5, e000688.	4.5	0
17	Experience with palliative sedation (PS) in an inpatient oncology setting Journal of Clinical Oncology, 2016, 34, e21503-e21503.	1.6	Ο
18	Experience with palliative sedation (PS) in an inpatient oncology setting Journal of Clinical Oncology, 2016, 34, 63-63.	1.6	0